Body Fat Reduction Effect of Bifidobacterium breve B-3: A Randomized, Double-Blind, Placebo Comparative Clinical Trial.
Hyun-Kyung SungSang Jun YounYong ChoiSang Won EunSeon Mi ShinPublished in: Nutrients (2022)
This double-blind, randomized clinical trial aimed to evaluate the efficacy and safety of Bifidobacterium breve B-3 (BB-3) for reducing body fat. Healthy individuals were randomized into the BB-3 or placebo group (1:1). Dual-energy X-ray absorptiometry was used to evaluate body fat reduction objectively. In the BB-3 group, body weight was lower than before BB-3 ingestion. Regarding waist circumference, hip circumference, and waist/hip circumference ratio, waist circumference and hip circumference were lower in the BB-3 group than in the placebo group at 12 weeks; the waist/hip circumference ratio was found to decrease at each visit in the BB-3 group, although there was no significant difference in the amount of change after 12 weeks. BB-3 did not cause any severe adverse reactions. Body fat was significantly lower in the BB-3 group than in the placebo group. In conclusion, ingesting BB-3 significantly reduces body weight, waist circumference, and hip circumference. Thus, BB-3 is safe and effective for reducing body fat.
Keyphrases
- body weight
- double blind
- body mass index
- growth factor
- placebo controlled
- clinical trial
- recombinant human
- phase iii
- dual energy
- phase ii
- physical activity
- total hip arthroplasty
- computed tomography
- open label
- emergency department
- randomized controlled trial
- high resolution
- magnetic resonance imaging
- early onset
- mass spectrometry
- gestational age
- preterm birth